Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Real Time Quote from BATS)
$32.92 USD
+1.17 (3.69%)
Updated Nov 19, 2024 12:22 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GPCR 32.92 +1.17(3.69%)
Will GPCR be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Other News for GPCR
Morgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Logos Global Management LP Adjusts Stake in Unicycive Therapeutics Inc
Logos Global Management LP Adjusts Stake in Elevation Oncology Inc
Logos Global Management LP Adjusts Stake in aTyr Pharma Inc
Logos Global Management LP Reduces Stake in NextCure Inc